2 recruiting, 1 terminated, 1 unknown, 1 withdrawn. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Terminated 1, Unknown 1, Withdrawn 1 |
Follow Microsatellite Stable Metastatic Colorectal Cancer: new trials by email Literature Review of Microsatellite Stable Metastatic Colorectal Cancer trials Research Report on Microsatellite Stable Metastatic Colorectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) Tiragolumab, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT) - Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-08-15 | 2026-02-19 | |
| Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer Ultra-fractionated radiation therapy, Sintilimab, Standard systemic therapy - Microsatellite Stable Metastatic Colorectal Cancer | Phase 2 | Recruiting | Fudan University | 116 | 2024-09-30 | 2026-10-19 |
| Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab - Microsatellite Stable Metastatic Colorectal Cancer | Phase 2 | Recruiting | Fudan University | 96 | 2024-04-01 | 2024-07-29 |
| Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer Regorafenib, Toripalimab, Radiotherapy - Microsatellite Stable Metastatic Colorectal Cancer | Phase 2 | Unknown | Fudan University | 108 | 2023-04-25 | 2024-09-24 |
| Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer Evorpacept (ALX148), Cetuximab, Pembrolizumab - Microsatellite Stable Metastatic Colorectal Cancer | Phase 2 | Terminated | University of Colorado, Denver | 19 | 2022-07-28 | 2026-09-03 |
Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Rectal Diseases (2)
toripalimab (2) · ALX148 (1) · Cetuximab (1) · Radiosurgery (1) · Radiotherapy (1) · Tiragolumab (1) · atezolizumab (1) · pembrolizumab (1) · regorafenib (1) · sintilimab (1)
Fudan University (3) · National Cancer Institute (NCI) (1) · University of Colorado, Denver (1)
China (3) · United States (2)
Tim F Greten, M.D. (1) · Wells Messersmith, MD (1) · Zhen Zhang, MD, PHD (1)